In contrast, the low-risk group comprises patients with highly immunogenic TME (high immune infiltrate content of the five biomarkers), and a high level of expression of the gene signature CXCL13 and HLA-DR, contributing to an effective anti-tumor response, preventing tumor cells from escaping the immune surveillance system, benefiting from immunotherapy, lowering the risk of recurrence and improving survival rates. Here, CXCL13 is linked to neoplasm.